Cargando…
Concurrent cisplatin or cetuximab with radiotherapy in patients with locally advanced head and neck squamous cell carcinoma: A meta-analysis
BACKGROUND: Concurrent cisplatin with radiotherapy (CRT) or concurrent cetuximab with radiotherapy (BRT) improves outcomes in locally advanced head and neck squamous cell carcinoma (HNSCC) compared with radiotherapy alone. Nevertheless, a detailed comparison between CRT and BRT in locally advanced H...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7478598/ https://www.ncbi.nlm.nih.gov/pubmed/32899005 http://dx.doi.org/10.1097/MD.0000000000021785 |
_version_ | 1783580088238866432 |
---|---|
author | Tang, Wen-Hua Sun, Wei Long, Guo-Xian |
author_facet | Tang, Wen-Hua Sun, Wei Long, Guo-Xian |
author_sort | Tang, Wen-Hua |
collection | PubMed |
description | BACKGROUND: Concurrent cisplatin with radiotherapy (CRT) or concurrent cetuximab with radiotherapy (BRT) improves outcomes in locally advanced head and neck squamous cell carcinoma (HNSCC) compared with radiotherapy alone. Nevertheless, a detailed comparison between CRT and BRT in locally advanced HNSCC is required due to inconclusive results. METHODS: A comprehensive literature search was conducted on PubMed, Web of Science, Cochrane databases, and EMBASE. Studies that evaluated CRT vs BRT in locally advanced HNSCC were included. The primary outcome that was overall survival (OS), whereas the secondary outcomes were progression-free survival (PFS), locoregional control (LRC), and distant metastasis-free survival (DMFS). Pooled hazard ratios (HRs) and the corresponding 95% confidence intervals (CIs) were used to evaluate prognosis. All the analyses were performed using Stata Statistical Software 12.0. RESULTS: Twenty-three studies, with a total of 8701 patients, were considered eligible and included in this meta-analysis. Our results revealed that patients treated with CRT had longer OS (HR = 0.51, 95%CI, 0.41–0.64, P < .001), PFS (HR = 0.37, 95%CI, 0.23–0.60, P < .001), LRC (HR = 0.46, 95%CI, 0.37–0.57, P < .001), and DMFS (HR = 0.56, 95%CI, 0.40–0.77, P < .001) than those treated with BRT. Furthermore, the results of the subgroup analyses were consistent with the primary analysis. CONCLUSIONS: CRT has a better OS, PFS, LRC, and DMFS than BRT in locally advanced HNSCC, and should be the preferred treatment for patients with the disease. |
format | Online Article Text |
id | pubmed-7478598 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-74785982020-09-24 Concurrent cisplatin or cetuximab with radiotherapy in patients with locally advanced head and neck squamous cell carcinoma: A meta-analysis Tang, Wen-Hua Sun, Wei Long, Guo-Xian Medicine (Baltimore) 5700 BACKGROUND: Concurrent cisplatin with radiotherapy (CRT) or concurrent cetuximab with radiotherapy (BRT) improves outcomes in locally advanced head and neck squamous cell carcinoma (HNSCC) compared with radiotherapy alone. Nevertheless, a detailed comparison between CRT and BRT in locally advanced HNSCC is required due to inconclusive results. METHODS: A comprehensive literature search was conducted on PubMed, Web of Science, Cochrane databases, and EMBASE. Studies that evaluated CRT vs BRT in locally advanced HNSCC were included. The primary outcome that was overall survival (OS), whereas the secondary outcomes were progression-free survival (PFS), locoregional control (LRC), and distant metastasis-free survival (DMFS). Pooled hazard ratios (HRs) and the corresponding 95% confidence intervals (CIs) were used to evaluate prognosis. All the analyses were performed using Stata Statistical Software 12.0. RESULTS: Twenty-three studies, with a total of 8701 patients, were considered eligible and included in this meta-analysis. Our results revealed that patients treated with CRT had longer OS (HR = 0.51, 95%CI, 0.41–0.64, P < .001), PFS (HR = 0.37, 95%CI, 0.23–0.60, P < .001), LRC (HR = 0.46, 95%CI, 0.37–0.57, P < .001), and DMFS (HR = 0.56, 95%CI, 0.40–0.77, P < .001) than those treated with BRT. Furthermore, the results of the subgroup analyses were consistent with the primary analysis. CONCLUSIONS: CRT has a better OS, PFS, LRC, and DMFS than BRT in locally advanced HNSCC, and should be the preferred treatment for patients with the disease. Lippincott Williams & Wilkins 2020-09-04 /pmc/articles/PMC7478598/ /pubmed/32899005 http://dx.doi.org/10.1097/MD.0000000000021785 Text en Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0 |
spellingShingle | 5700 Tang, Wen-Hua Sun, Wei Long, Guo-Xian Concurrent cisplatin or cetuximab with radiotherapy in patients with locally advanced head and neck squamous cell carcinoma: A meta-analysis |
title | Concurrent cisplatin or cetuximab with radiotherapy in patients with locally advanced head and neck squamous cell carcinoma: A meta-analysis |
title_full | Concurrent cisplatin or cetuximab with radiotherapy in patients with locally advanced head and neck squamous cell carcinoma: A meta-analysis |
title_fullStr | Concurrent cisplatin or cetuximab with radiotherapy in patients with locally advanced head and neck squamous cell carcinoma: A meta-analysis |
title_full_unstemmed | Concurrent cisplatin or cetuximab with radiotherapy in patients with locally advanced head and neck squamous cell carcinoma: A meta-analysis |
title_short | Concurrent cisplatin or cetuximab with radiotherapy in patients with locally advanced head and neck squamous cell carcinoma: A meta-analysis |
title_sort | concurrent cisplatin or cetuximab with radiotherapy in patients with locally advanced head and neck squamous cell carcinoma: a meta-analysis |
topic | 5700 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7478598/ https://www.ncbi.nlm.nih.gov/pubmed/32899005 http://dx.doi.org/10.1097/MD.0000000000021785 |
work_keys_str_mv | AT tangwenhua concurrentcisplatinorcetuximabwithradiotherapyinpatientswithlocallyadvancedheadandnecksquamouscellcarcinomaametaanalysis AT sunwei concurrentcisplatinorcetuximabwithradiotherapyinpatientswithlocallyadvancedheadandnecksquamouscellcarcinomaametaanalysis AT longguoxian concurrentcisplatinorcetuximabwithradiotherapyinpatientswithlocallyadvancedheadandnecksquamouscellcarcinomaametaanalysis |